"Since starting Ampyra, I have the confidence in my ability to do simple things, like keeping up? to meet friends" -Kristie
Questions? 1-888-881-1918


Evaluate your walking ability

Multiple sclerosis (MS) affects people’s walking differently and it’s important to let your healthcare professional know about symptoms you’re experiencing.

To help you evaluate your current walking ability, we have developed a personalized tool that you can bring with you to your next doctor’s appointment. This Self-Assessment is based on the 12-Item Multiple Sclerosis Walking Scale (or MSWS-12)—a scale that can be used by people with MS to rate the impact of MS on their walking ability.

Start assessing your walking now

Or, if you are in a hurry...

pdf icon image

About PDF Files
PDF stands for "Portable Document Format." PDF files require Adobe Acrobat Reader, which can be downloaded free from the Adobe website at www.adobe.com.

Important notice: Acorda respects your right to have personal and medical information kept confidential. Acorda
cannot access this information.


AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with MS. AMPYRA improved walking in significantly more people with MS than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%). This was demonstrated by an increase in walking speed. In the clinical studies, people who walked faster, regardless of treatment, also reported improvements in their walking-related activities. This was shown using the 12-Item Multiple Sclerosis Walking Scale (or MSWS-12).

Not everyone responds to AMPYRA. Individual results may vary.

A drug/placebo difference was not established for this outcome measure.

AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.


Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.

AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.

Before taking AMPYRA tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.

Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.

Please see the full Prescribing Information and Patient Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AMPYRA®, ACORDA THERAPEUTICS® and the stylized ACORDA THERAPEUTICS® logo are registered trademarks of Acorda Therapeutics, Inc. | AMPYRA® is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland. | AMPYRACONNECT™ is a trademark of Acorda Therapeutics, Inc. | The stylized path logo and the stylized Acorda logo are trademarks of Acorda Therapeutics, Inc. | © 2013 Acorda Therapeutics, Inc. All rights reserved.